BeiGene Announces Clinical Data on Tislelizumab and Zanubrutinib to be Presented at the 24th Congress of the European Hematology Association
CAMBRIDGE, Mass. and BEIJING, China, May 16, 2019 (GLOBE NEWSWIRE) -- BeiGene, Ltd. (NASDAQ: BGNE; HKEX: 06160), a commercial-stage biopharmaceutical company focused on developing and commercializing innovative molecularly-targeted and immuno-oncology drugs for the treatment of cancer, today announced data presentations on its investigational anti-PD-1 antibody tislelizumab and its investigational BTK inhibitor zanubrutinib from four posters at the 24th Congress of the European Hematology Association (EHA), taking place June 13-16, 2019 in Amsterdam.
Poster Presentations:
| Title: | Tislelizumab (BGB-A317) for relapsed/refractory classical Hodgkin lymphoma: updated follow-up efficacy and safety results from a Phase 2 study |
| Abstract Code: | PF469 |
| Session Title: | Hodgkin lymphoma – Clinical |
| Date: | Friday, June 14 |
| Time: | 17:30 – 19:00 (CEST) |
| Lead Author: | Yuqin Song, M.D., Ph.D. |
| Title: | Major responses in MYD88 wildtype (MYD88WT) Waldenström Macroglobulinemia (WM) patients treated with Bruton Tyrosine Kinase (BTK) inhibitor zanubrutinib (BGB-3111) |
| Abstract Code: | PF487 |
| Session Title: | Indolent and mantle-cell non-Hodgkin lymphoma – Clinical |
| Date: | Friday, June 14 |
| Time: | 17:30 – 19:00 (CEST) |
| Lead Author: | Meletios A. Dimopoulos, M.D. |
| Title: | Updated safety and efficacy data in a Phase 1/2 trial of patients with Waldenström Macroglobulinaemia (WM) treated with the Bruton Tyrosine Kinase (BTK) inhibitor zanubrutinib (BGB-3111) |
| Abstract Code: | PF481 |
| Session Title: | Indolent and mantle-cell non-Hodgkin lymphoma – Clinical |
| Date: | Friday, June 14 |
| Time: | 17:30 – 19:00 (CEST) |
| Lead Author: | Judith Trotman, MBChB, FRACP, FRCPA |
| Title: | Pooled analysis of safety data from monotherapy studies of the Bruton Tyrosine Kinase (BTK) inhibitor, zanubrutinib (BGB-3111), in B-cell malignancies |
| Abstract Code: | PS1159 |
| Session Title: | Chronic lymphocytic leukemia and related disorders – Clinical |
| Date: | Saturday, June 15 |
| Time: | 17:30 – 19:00 (CEST) |
| Lead Author: | Constantine S. Tam, M.D. |
About BeiGene
BeiGene is a global, commercial-stage, research-based biotechnology company focused on molecularly-targeted and immuno-oncology cancer therapeutics. With a team of over 2,400 employees in China, the United States, Australia and Europe, BeiGene is advancing a pipeline consisting of novel oral small molecules and monoclonal antibodies for cancer. BeiGene is also working to create combination solutions aimed to have both a meaningful and lasting impact on cancer patients. BeiGene markets ABRAXANE® (nanoparticle albumin-bound paclitaxel), REVLIMID® (lenalidomide), and VIDAZA® (azacitidine) in China under a license from Celgene Corporation.i
Investor Contact Media Contact
Craig West Liza Heapes
i ABRAXANE®, REVLIMID®, and VIDAZA® are registered trademarks of Celgene Corporation
